IPO Prospectus

IPO Prospectus2020-12-10T06:03:50+00:00

Chimeric Therapeutics Limited ACN 638 835 828 (Chimeric) lodged a Prospectus for an offer of 175,000,000 shares in Chimeric to raise $35 million at an offer price of $0.20 per share (Offer) with the Australian Securities & Investments Commission on 23 November 2020. The Prospectus details the terms of the Offer.  

Chimeric advises that, due to overwhelming support and significant oversubscriptions, the Offer will be closing early at 5.00pm Thursday, 10 December.  The balance of the timetable set out in the prospectus currently remains unchanged.

Call the Chimeric Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm AEST if you have any questions in relation to the Offer.

Chimeric Therapeutics Limited notice to prospective investors – website disclaimer

1 Important notice
The information on this page is not part of the Prospectus.  You must read this notice before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement at the bottom of this notice.  If you agree to these conditions, you will be given access to the electronic Prospectus.

2 Date and duration of Offer
Chimeric Therapeutics Limited ACN 638 835 828 (Chimeric) lodged a Prospectus for an offer of 175,000,000 shares in Chimeric to raise $35 million at an offer price of $0.20 per share (Offer) with the Australian Securities & Investments Commission on 23 November 2020. The Prospectus details the terms of the Offer.  The Offer period commences on 3 December 2020 and is expected to close on 14 December 2020.  Chimeric may vary these dates without notice.

3 Applications not accepted until offer period commences
Applications for Chimeric shares under the Prospectus will not be accepted by Chimeric until 3 December 2020 when the offer period commences.  Applications may only be made on the Application Forms attached to or accompanying the Prospectus (including the electronic copy of the Prospectus).  Applications will not be processed until after the offer period commences and no preference will be conferred on Applications received prior to commencement of the offer period.  Chimeric will not accept a completed Application Form if it is has reason to believe that (a) the applicant has not received a complete paper copy or the electronic copy of the Prospectus, or (b) the Application Form or electronic copy of the Prospectus has been altered or tampered with in any way.

4 Jurisdiction
Access to the electronic version of the Prospectus is only available to persons resident in Australia with a registered address in Australia, from within Australia.  The distribution of this Prospectus in jurisdictions outside of Australia may be restricted by law and persons in such jurisdictions who come into possession of the Prospectus should seek advice on and observe any such restrictions.  Any failure to comply with such restrictions may constitute a violation of applicable securities laws.  The Prospectus does not constitute an offer or an invitation in any jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation.  No action has been taken to register the Prospectus or otherwise permit a public offering of Chimeric’s shares in any jurisdiction outside Australia.  The Prospectus provided on the Chimeric website is available to persons accessing this website from within Australia only.  If you are accessing this site from anywhere outside Australia, do not download, print or view the Prospectus accessible through this web page.  By accessing the Prospectus, you acknowledge and confirm that you are accessing this website from within Australia.

5 Investors should seek advice
Nothing contained on this website or in the Prospectus constitutes investment, legal, business, tax or other advice.  If you are in doubt as to how to deal with the Prospectus or Application Form, please contact your accountant, lawyer, stockbroker or other professional adviser.  The Prospectus contains information relevant to a decision to invest in shares and the risks associated with that investment.  You should read the entire Prospectus carefully before applying for shares.

6 Privacy
To access the electronic version of the Prospectus you may be required to provide personal information to Chimeric.  Chimeric collects, holds and will use that information to assess your Application (should you make one) and to communicate and provide services to you.  Chimeric may disclose information to its agents, related bodies corporate, associates, service providers (such as the share registry) and government bodies.  You may access, correct and update the personal information that Chimeric holds about you by contacting the share registry.

7 Acceptance of conditions
By proceeding, I agree to the above statements, and confirm that I am a resident of Australia accessing this website from within Australia.  In addition, I represent, warrant and agree that I am not a resident of the United States or currently located in the United States, nor am I acting for the account or benefit of any person in the United States, a US person or any other foreign person, and that I will not make a copy of the Prospectus available to, or distribute a copy of the Prospectus to, any such non-Australian resident person.

Agree
I do not agree